Concepedia

Jesse Brodkin

JB

19

Publications

2.3K

Citations

18

H-Index

1991

Active since

Affiliations

General Atomics (United States)(Current)

Case Western Reserve University

Merck & Co., Inc., Rahway, NJ, USA (United States)

Eli Lilly (United States)

National Institute of Diabetes and Digestive and Kidney Diseases

Jesse Brodkin is an author at General Atomics (United States) specializing in medicine, pharmacology, and neuropharmacology.

Top concepts

Publications per year

1991–2014

19

Publications

19

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine:  A Potent and Highly Selective Metabotropic Glutamate Subtype 5 Receptor Antagonist with Anxiolytic Activity

Nicholas D. P. Cosford, Lida Tehrani, Jeffrey Roppe et al. · Journal of Medicinal Chemistry · 2002 · 400 citations · Full text

, , +17

Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice

Jesús Gomeza, Harlan E. Shannon, Evi Kostenis et al. · Proceedings of the National Academy of Sciences · 1999 · 350 citations

, , +17

Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M <sub>4</sub> muscarinic acetylcholine receptor knockout mice

Jesús Gomeza, Lu Zhang, Evi Kostenis et al. · Proceedings of the National Academy of Sciences · 1999 · 319 citations

, , +17

The Behavioral Profile of the Potent and Selective mGlu5 Receptor Antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in Rodent Models of Anxiety

Chris S Busse, Jesse Brodkin, David Tattersall et al. · Neuropsychopharmacology · 2004 · 157 citations · Full text

, , +11

Anxiolytic-like activity of the mGluR5 antagonist MPEPA comparison with diazepam and buspirone

Jesse Brodkin, Chris S Busse, Stacey J. Sukoff Rizzo et al. · Pharmacology Biochemistry and Behavior · 2002 · 144 citations

, , +7

Rows per page

1–5 of 19